Although the potency of these compounds was lower compared to known HDACi TSA, apicidin and depsipeptide, they had comparable or greater selectivity of inhibition for cancer vs. normal cells and for HDAC6 vs HDAC1. This evidence concerns the gene HDAC6 and cancer.